Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jinhai Medical TechnologyHKSE:02225 -7.14%61 OCF Margin % is 9.90% as of Dec. 2025, which is 65% above its 10-year median of 6.00. GuruFocus rates HKSE:02225 with a GF Score™ of 61/100 and a GF Value™ of HK$1.41 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 534 Conglomerates companies, Jinhai Medical Technology ranks worse than 88.2% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02225 vs RHI, KFY, TNET: OCF Margin % Comparison
For the Conglomerates subindustry, Jinhai Medical Technology's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinhai Medical Technology OCF Margin % vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Jinhai Medical Technology's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Jinhai Medical Technology's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jinhai Medical Technology (HKSE:02225) has a OCF Margin % of 9.90% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Jinhai Medical Technology and its competitors. This is 65% above median its historical median of 6.00. According to the industry distribution chart, Jinhai Medical Technology ranks #471 out of 534 companies in the Conglomerates industry, placing it in the top 88.2%.
Is Jinhai Medical Technology's OCF Margin % too high?
Jinhai Medical Technology's current OCF Margin % of 9.90% is 65% above median its 10-year median of 6.00. The Conglomerates industry median OCF Margin % is 6.74. Jinhai Medical Technology's value of 9.90% is 47% above this industry median. Based on the distribution chart, Jinhai Medical Technology ranks #471 out of 534 companies in the Conglomerates industry, which is in the bottom quartile relative to peers. Overall, Jinhai Medical Technology has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinhai Medical Technology's OCF Margin % compare to RHI and KFY?
According to the Conglomerates industry distribution chart, Jinhai Medical Technology ranks #471 out of 534 companies for OCF Margin %. This places Jinhai Medical Technology in the lower half of its industry. The industry median OCF Margin % is 6.74. Jinhai Medical Technology's value of 9.90% is 47% above this benchmark. While the company's 10-year median is 6.00 vs. the industry median of 6.74, Jinhai Medical Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Conglomerates company?
The median OCF Margin % among Conglomerates companies is 6.74, based on 534 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jinhai Medical Technology's current OCF Margin % of 9.90% is 47% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Jinhai Medical Technology and its competitors. For the Conglomerates industry, the median OCF Margin % is 6.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinhai Medical Technology's current OCF Margin % is 9.90%, which is 65% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinhai Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Jinhai Medical Technology (HKSE:02225) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.41, compared to a current price of HK$6.05 — trading 328.7% above its estimated fair value. The current OCF Margin % is 9.90%, which is 65% above median its 10-year median of 6.00 and 47% above the Conglomerates industry median of 6.74. Jinhai Medical Technology's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Jinhai Medical Technology (HKSE:02225), the current OCF Margin % is 9.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinhai Medical Technology (HKSE:02225) Overvalued in 2026?
Based on GuruFocus' analysis, Jinhai Medical Technology stock appears to be overvalued.
The current stock price of HK$6.05 is trading 328.7% above its estimated GF Value™ of HK$1.41.
GuruFocus considers Jinhai Medical Technology to be Significantly Overvalued.
Key valuation signals for HKSE:02225:
OCF Margin %: 9.90% (65% above median its 10-year median of 6.00)
GF Value™: HK$1.41 vs. price of HK$6.05 (328.7% above fair value)
Industry Position: 47% above the Conglomerates median (#471 of 534)
No single metric tells the full story. See the HKSE:02225 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinhai Medical Technology Ltd is an investment holding company. Along with its subsidiaries, it is principally engaged in providing medical equipment in China and manpower outsourcing and ancillary services to building and construction contractors in Singapore. The group also provides IT services, construction ancillary services (which comprise warehousing, cleaning, and building maintenance works), and dormitory services in Singapore. It generates maximum revenue from the sale of minimally invasive surgery solutions, medical products, and related services in the People's Republic of China.
61GF Score
Get the complete analysis for HKSE:02225
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02225 has been successfully added to your 
